Tags

Type your tag names separated by a space and hit enter

MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome.
BMC Cancer. 2010 Sep 17; 10:497.BC

Abstract

BACKGROUND

The four-transmembrane MAL2 protein is frequently overexpressed in breast carcinoma, and MAL2 overexpression is associated with gain of the corresponding locus at chromosome 8q24.12. Independent expression microarray studies predict MAL2 overexpression in ovarian carcinoma, but these had remained unconfirmed. MAL2 binds tumor protein D52 (TPD52), which is frequently overexpressed in ovarian carcinoma, but the clinical significance of MAL2 and TPD52 overexpression was unknown.

METHODS

Immunohistochemical analyses of MAL2 and TPD52 expression were performed using tissue microarray sections including benign, borderline and malignant epithelial ovarian tumours. Inmmunohistochemical staining intensity and distribution was assessed both visually and digitally.

RESULTS

MAL2 and TPD52 were significantly overexpressed in high-grade serous carcinomas compared with serous borderline tumours. MAL2 expression was highest in serous carcinomas relative to other histological subtypes, whereas TPD52 expression was highest in clear cell carcinomas. MAL2 expression was not related to patient survival, however high-level TPD52 staining was significantly associated with improved overall survival in patients with stage III serous ovarian carcinoma (log-rank test, p < 0.001; n = 124) and was an independent predictor of survival in the overall carcinoma cohort (hazard ratio (HR), 0.498; 95% confidence interval (CI), 0.34-0.728; p < 0.001; n = 221), and in serous carcinomas (HR, 0.440; 95% CI, 0.294-0.658; p < 0.001; n = 182).

CONCLUSIONS

MAL2 is frequently overexpressed in ovarian carcinoma, and TPD52 overexpression is a favourable independent prognostic marker of potential value in the management of ovarian carcinoma patients.

Authors+Show Affiliations

Molecular Oncology Laboratory, Children's Cancer Research Unit, The Children's Hospital at Westmead, Westmead, New South Wales, Australia. JennifeB@chw.edu.auNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20846453

Citation

Byrne, Jennifer A., et al. "MAL2 and Tumor Protein D52 (TPD52) Are Frequently Overexpressed in Ovarian Carcinoma, but Differentially Associated With Histological Subtype and Patient Outcome." BMC Cancer, vol. 10, 2010, p. 497.
Byrne JA, Maleki S, Hardy JR, et al. MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome. BMC Cancer. 2010;10:497.
Byrne, J. A., Maleki, S., Hardy, J. R., Gloss, B. S., Murali, R., Scurry, J. P., Fanayan, S., Emmanuel, C., Hacker, N. F., Sutherland, R. L., Defazio, A., & O'Brien, P. M. (2010). MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome. BMC Cancer, 10, 497. https://doi.org/10.1186/1471-2407-10-497
Byrne JA, et al. MAL2 and Tumor Protein D52 (TPD52) Are Frequently Overexpressed in Ovarian Carcinoma, but Differentially Associated With Histological Subtype and Patient Outcome. BMC Cancer. 2010 Sep 17;10:497. PubMed PMID: 20846453.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome. AU - Byrne,Jennifer A, AU - Maleki,Sanaz, AU - Hardy,Jayne R, AU - Gloss,Brian S, AU - Murali,Rajmohan, AU - Scurry,James P, AU - Fanayan,Susan, AU - Emmanuel,Catherine, AU - Hacker,Neville F, AU - Sutherland,Robert L, AU - Defazio,Anna, AU - O'Brien,Philippa M, Y1 - 2010/09/17/ PY - 2010/04/07/received PY - 2010/09/17/accepted PY - 2010/9/18/entrez PY - 2010/9/18/pubmed PY - 2011/2/4/medline SP - 497 EP - 497 JF - BMC cancer JO - BMC Cancer VL - 10 N2 - BACKGROUND: The four-transmembrane MAL2 protein is frequently overexpressed in breast carcinoma, and MAL2 overexpression is associated with gain of the corresponding locus at chromosome 8q24.12. Independent expression microarray studies predict MAL2 overexpression in ovarian carcinoma, but these had remained unconfirmed. MAL2 binds tumor protein D52 (TPD52), which is frequently overexpressed in ovarian carcinoma, but the clinical significance of MAL2 and TPD52 overexpression was unknown. METHODS: Immunohistochemical analyses of MAL2 and TPD52 expression were performed using tissue microarray sections including benign, borderline and malignant epithelial ovarian tumours. Inmmunohistochemical staining intensity and distribution was assessed both visually and digitally. RESULTS: MAL2 and TPD52 were significantly overexpressed in high-grade serous carcinomas compared with serous borderline tumours. MAL2 expression was highest in serous carcinomas relative to other histological subtypes, whereas TPD52 expression was highest in clear cell carcinomas. MAL2 expression was not related to patient survival, however high-level TPD52 staining was significantly associated with improved overall survival in patients with stage III serous ovarian carcinoma (log-rank test, p < 0.001; n = 124) and was an independent predictor of survival in the overall carcinoma cohort (hazard ratio (HR), 0.498; 95% confidence interval (CI), 0.34-0.728; p < 0.001; n = 221), and in serous carcinomas (HR, 0.440; 95% CI, 0.294-0.658; p < 0.001; n = 182). CONCLUSIONS: MAL2 is frequently overexpressed in ovarian carcinoma, and TPD52 overexpression is a favourable independent prognostic marker of potential value in the management of ovarian carcinoma patients. SN - 1471-2407 UR - https://www.unboundmedicine.com/medline/citation/20846453/MAL2_and_tumor_protein_D52__TPD52__are_frequently_overexpressed_in_ovarian_carcinoma_but_differentially_associated_with_histological_subtype_and_patient_outcome_ L2 - https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-10-497 DB - PRIME DP - Unbound Medicine ER -